Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMBS....story will be told August 05,...says, "THE CRYSTAL BALL". A DAY LATER... AMBS STORY TOLD; says, "THE CRYSTAL BALL"
AMBS, BOL
noinsiderinfo here!!! :)
AMBS.....TOTALLY AGREE...I am in this til the end... It hurts to look @ it and think about it..But I have sucked this scenario in and averaging down every month. Public school starts again very soon. Between teaching, tutoring and other incomes I'd say I'll be throwing in the kitchen sink.... but I refuse to throw in the towel.
The TITANTIC WILL HAVE TO "SAIL OR SINK"!!
AMBS
AMBS....a little humor goes a long way " SAYS, THE CRYSTAL BALL" when you are in the red $$ like myself ... the game is not over unless you sell.... STILL IN THE GAME$.
AMBS..BOL
P.S. the dawn of tomorrow has not come says, "THE CRYSTAL BALL"
1. HOPE
2. BELIEVE.... JUST BELIEVE
3.WAIT.. WAIT..WAIT SOME MORE!
4.PATIENCE
GO AMBS
AMBS....@ LUNCH THROUGH 1:30PM; and again @3pm-4pm...SAYS, "THE CRYSTAL BALL"
AMBS..lmbo!
August 5th, says my "CRYSTAL BALL"
AMBS, lmbo
AMBS....... Story will unfold on August 05, 2013...... Read an article today that I won't Reveal the source of the article...
IT'S ALIVE????
KGRI
Agreed....quiet storm .... "And we were all gathered together on one accord" This board seems different.... A change is upon all. AMBS
WWW.STOCKTA.COM is 'VERY BULLISH' on AMBS
Chart Indicators
Ind. short Inter Long
EMA VBe Be VBe
MACD VBu VBu VBu
RSI Be
TDD Bu
Fibs Bu VBe VBe
Highs VBe N N
Lows Be N VBu
Trends Be Be Bu
Stoch. Bu
VBu=Very Bullish, Bu=Bullish
N=Neutral
Be=Bearish, VBe=Very Bearish
Read more at http://www.stockta.com/cgi-bin/analysis.pl?symb=AMBS&cobrand=&mode=stock#j1Qe3XymgvxmhVyf.99
IMPRESSIVE PENNIES are promoting AMBS
'LIKE'
AMBS
New Research Emerges For Parkinson's
.
Posted: Tuesday, June 18, 2013 2:21 pm | Updated: 2:31 am, Wed Jun 19, 2013.
New Research Emerges For Parkinson's NewsUSA@NewsUSA.com (NewsUSA) Bloomer Advance | 0 comments
(NewsUSA) - People often believe the myth that Parkinson's disease only afflicts the elderly, but research indicates that a growing number of middle-aged adults are developing the neurodegenerative disorder. The National Parkinson Foundation reports that 10 percent of people with Parkinson's are diagnosed before age 40.
Although there are effective ways to deal with the symptoms of Parkinson's -- exercise, brain stimulation, dopamine replacement drugs -- diagnostic tests and curative treatments still have a long way to go.
"Existing approved therapies only treat the symptoms of Parkinson's," explains Gerald E. Commissiong, president and CEO of Amarantus BioScience Holdings, Inc. (OTCQB:AMBS) -- a biotechnology company that focuses developing new treatments for neurodegenerative conditions. "A therapeutic protein called MANF (Mesencephalic Astrocyte-derived Neurotrophic Factor) has shown the potential to rejuvenate dying cells and protect the neurons that produce dopamine in rodents."
Parkinson's belongs to a group of conditions known as motor system disorders, in which the brain cells that generate dopamine start to die. Symptoms typically get progressively worse, including trembling in the limbs and face, stiffness in the torso, slowness of movement, depression, trouble speaking and chewing and poor balance and coordination.
According to Commissiong, the therapeutic MANF program from Amarantus may eventually prevent Parkinson's from getting worse and possibly restore some normal cell function. The ability to prevent cell death -- otherwise known as apoptosis -- is vital. It could be used to treat Alzheimer's, stroke and traumatic brain injuries (TBIs).
Amarantus, a publicly traded company, also develops a diagnostic platform for Alzheimer's, Lou Gehrig's disease, breast cancer and Parkinson's.
To learn more about the therapeutic MANF program at Amarantus, visit www.amarantus.com.
Sounds like...(singing)
"pants on the ground, pants on the ground; looking like a fool ; witcha pants on the ground"
imo..GO AMBS
BD collaborates ..........collaboration with AMBS ....fruitful results are expected....as expected with BD collaborative engagements with other companies.
News for 'BDX' - (JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes Combination of BD's proprietary technologies represents critical step toward artificial pancreas)
FRANKLIN LAKES, N.J. and NEW YORK, June 18, 2013 /PRNewswire via COMTEX/ --
JDRF and BD (Becton, Dickinson and Company) (NYSE:BDX) are accelerating the
development of new products that combine BD's proprietary insulin infusion and
glucose sensing technologies through a new collaboration announced today. This
new, three-year commitment is an extension of existing JDRF-BD collaborations
focused on type 1 diabetes (T1D).
Many patients with T1D not only take daily insulin via an insulin pump -
requiring a catheter to be placed in the body for a number of days - but are
also checking their glucose levels via a continuous glucose monitor (CGM), which
also requires a catheter-like sensor to be placed in the body for a number of
days.
While BD has been working to improve the products used for insulin infusion and
CGM, the new collaboration with JDRF will enable additional research to develop
a single optimized device that will perform both functions and eliminate the
need and complexities of multiple in-dwelling catheters. The ability to perform
these discrete metabolic actions automatically and accurately, with little
patient intervention, defines the artificial pancreas concept.
"Providing the best tools that not only improve patient care, but ease the daily
burden of managing diabetes are important goals for BD and JDRF," said Linda
Tharby, President, BD Medical - Diabetes Care. "This latest collaboration with
JDRF demonstrates both parties' commitment to improve patients' experiences and
outcomes. Combining these novel technologies will address two key components of
an advanced artificial pancreas system."
"As the world's largest charitable funder of type 1 diabetes research, JDRF is
committed to advancing therapies that improve the lives of people living with
this disease," said Jeffrey Brewer, President and Chief Executive Officer of
JDRF. "We are excited to continue our collaboration with BD and support efforts
to develop novel technologies enabling advanced artificial pancreas systems that
will both measure glucose and administer insulin. Joining these capabilities
into a single solution will address significant patient needs and help reduce
the daily burden of managing type 1 diabetes."
T1D is an autoimmune disease in which the body's pancreas stops producing
insulin, a hormone needed to turn food into energy. BD's culture of innovation
and continuous improvement has enhanced the patient experience to help improve
therapy and outcomes for people with diabetes worldwide. BD devices support
earlier initiation and better adherence to prescribed therapies to help all
diabetes patients live healthier lives.
About BD BD is a leading global medical technology company that develops,
manufactures and sells medical devices, instrument systems and reagents. The
Company is dedicated to improving people's health throughout the world. BD is
focused on improving drug delivery, enhancing the quality and speed of
diagnosing infectious diseases and cancers, and advancing research, discovery
and production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates
in more than 50 countries throughout the world. The Company serves healthcare
institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
visit www.bd.com.
About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D)
research. JDRF's goal is to progressively remove the impact of T1D from people's
lives until we achieve a world without T1D. JDRF collaborates with a wide
spectrum of partners and is the only organization with the scientific resources,
regulatory influence, and a working plan to better treat, prevent, and
eventually cure T1D.
As the largest charitable supporter of T1D research, JDRF is currently
sponsoring $530 million in scientific research in 17 countries. In 2012 alone,
JDRF provided more than $110 million to T1D research. More than 80 percent of
JDRF's expenditures directly support research and research-related education. In
2012, Forbes magazine named JDRF one of its five All-Star charities, citing the
organization's efficiency and effectiveness. For more information, please visit
jdrf.org.
Contacts:
JDRF BD
AMBS...PATIENTLY WAITING.. AND WAIT SOME MORE $$.......my $8k is now more or less like $3k :(
GO AMBS..
News for 'AMBS' - (Amarantus Calls on BD Biosciences for Development of Alzheimer's Diagnostic)
Jun 18, 2013 (Close-Up Media via COMTEX) -- Amarantus BioScience Holdings,
Inc., a biotechnology company discovering and developing treatments and
diagnostics for diseases associated with neurodegeneration and apoptosis,
announced it has signed a laboratory services agreement with BD Biosciences, a
segment of BD (Becton, Dickinson and Company), a global medical technology
company, under which BD's BD Biosciences Custom Technology Team will perform
sample analysis on Amarantus' LymPro Test for Alzheimer's disease.
"The LymPro Test is potentially the first available blood test for Alzheimer's
disease," said Gerald E. Commissiong, President & CEO of Amarantus. "With this
agreement, we expect to have initial data available in the third quarter of
2013, and now have the capabilities required to place LymPro on a path for
commercialization in 2014."
According to a release, Amarantus and BD Biosciences will be focused on
verifying the analytical performance characteristics of LymPro necessary to
achieve reproducibility of the assay. Over time, Amarantus expects to execute
multiple clinical studies and begin worldwide sales of LymPro as a diagnostic
blood test for Alzheimer's disease.
Amarantus is a development-stage biotechnology company founded in January 2008.
More information:
Amarantus.com
THIS IS GOING DOWN "PAINFULLY"...YET IT IS GOING TO POP LIKE A BOX OF CRACKER JACKS....$$$$ SURPRISE$$$
AMBS
AMBS....dont hate the player(s).....HATE THE GAME!! this is the game that you/we play when investing... AMBS will MATURE someday/sometime in the future... just not right now
MY SELL ORDER @ $10. will get filled SOMEDAY!!! YOU SEE the REST OF AMBS INVESTORS ARE JUST PLAYING THE GAME... AND NOT WHINING. I have lost many times in the past... never could I whine about it publicly!!! ijs..
AMBS
WELCOME HOME CHETRA !!! GLAD TO SEE YOU AGAIN....HOW ARE YOU????
ARE YOU OUTA JAIL TO STAY OUT?.... OR IS THIS A TEMPORARY REPRIEVE?
UNGS
I MISSED YOU!!
High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our Ts&Cs and Copyright Policy for more detail. Email ftsales.support@ft.com to buy additional rights. www.ft.com/cms/s/0/9a2250c4-c2eb-11e2-9bcb-00144feab7de.html#ixzz2UUouCpil
Investors pour big sums into US biotech
By Arash Massoudi in New York
One of Wall Street’s riskiest equity bets is back. In a quest to find the next big medical breakthrough, stock market investors have poured $725m into 10 biotechnology flotations that are attempting to create drugs for illnesses including multiple scelorsis and hepatitis C.
The resurgent mood in the US equity market has proved a boon for these companies, usually ranked among the most speculative investments, as they try to come up with the next medical miracle.
More
ON THIS STORY
Investors bet on biotech success
Biotech surge powers ETF inflows
Video Biotech high
The Short View Beware side-effects of biotech boom
Former Nice chief’s new job stirs concern
ON THIS TOPIC
Chinese broker Galaxy enjoys strong debut
US housing groups to launch IPOs
Griffiths Energy eyes London listing
Buyout group Ares prepares for IPO
IN US EQUITIES
US stocks step back from intraday highs
US stocks close at fresh high
Move into ‘junk’ stocks powers bull run
Short position holders have been hit hard
The result has been that small biotechs, which struggle to generate interest from credit investors since they lack cash flow, are pursuing US initial public offerings at the fastest pace in nearly a decade.
Ten biotech companies have listed on the US market so far this year, accounting for 14 per cent of all US IPOs, and at least another seven are preparing a float in the coming months, according to data from Dealogic.
With industry data showing on average that just one in 10 biotech companies successfully launch a drug product, the risks are high. But the right investment in a company promising a breakthrough can lead to outsize returns for early investors.
The leap in listings comes as publicly traded biotechnology companies have outperformed. The Nasdaq Biotechnology Index has risen 32 per cent since the start of the year, eclipsing its previous record high set during the dotcom era and far outgaining the S&P 500’s 16 per cent rise.
“There is definitely an increase in risk-taking going on given the extent to which the industry has outperformed the market,” said Steven Silver, biotechnology analyst at S&P Capital IQ.
The interest in biotech stocks has come from a broad base of risk-seeking investors and has been fuelled by the knock-on effects of global monetary easing. Bankers said it had never been easier to bring a biotech company to market, with deals pricing at unusually strong levels.
Buy-side investors ranging from hedge funds to institutional investors were reviewing investment opportunities in the sector, bankers said. The deals have typically been the domain of niche, specialist firms.
This risk-taking has allowed companies in earlier stages of the drug development process, including some that have not had a clinical trial, to come to market.
“A general rule that a biotech company had to have hit a certain phase of progress is no longer true,” said Michael Zeidel, a capital markets attorney at Skadden, Arps, Slate, Meagher & Flom. “There’s certainly more deals getting done now from companies in the earlier stages of drug development.”
Mr Silver added that long-term industry records showed there was just a 10 per cent success rate for a biotech company bringing a drug to market.
The sector has also been one of the biggest beneficiaries of the Jumpstart Our Business Startups (Jobs) Act, which came into force last April and was designed to make it easier for start-ups to launch an IPO.
Copyright The Financial Times Limited 2013. You may share using our article tools.
Please don't cut articles from FT.com and redistribute by email or post to the web.
YOU "SAID THAT !!".. SAY IT AGAIN !!!
AMBS
NEWS OUT !!!
Account" tab.
News for 'AMBS' - (Amarantus BioScience President and CEO Publishes New Blog Entitled ''Continued Progress with our Business Plan in Central Nervous System Disorders'')
May 16, 2013 (ACCESSWIRE-TNW via COMTEX) -- Amarantus BioScience, Inc. (OTCQB:
AMBS) today published a blog post entitled "Continued Progress with our Business
Plan in Central Nervous System Disorders" on TheChairmansBlog.com.
Amarantus President and CEO, Gerald Commissiong, updates shareholders on an
"aggressive growth strategy for the Company's key products, MANF and LymPro."
Mr. Commissiong explains how the Company seeks to create multiple opportunities
and mitigate risk in both of its Therapeutics and Diagnostics divisions. Read
the full blog post from Gerald Commissiong on TheChairmansBlog.com
(http://www.thechairmansblog.com/gerald-commissiong/2013-05/continued-progress-with-our-business-plan-in-central-nervous-system-disorders.html).
About Amarantus BioScience, Inc.
AmarantusBioScience, Inc. is a development-stage biotechnology company founded
in January 2008. The Company has a focus on developing certain biologics
surrounding the intellectual property and proprietary technologies it owns to
treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other
human diseases. The Company owns the intellectual property rights to a
therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor
("MANF") and is developing MANF-based products as treatments for brain
disorders. The Company also is a Founding Member of the Coalition for Concussion
Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports
International seeking to raise awareness of new treatments in development for
concussions and nervous-system disorders. For further information, please visit
www.amarantus.com.
About TheChairmansBlog.com
OTCBB Journal PROMO
"Be ready, New feature coming Tomorrow morning at 9 AM
This next pick is around .05/share and has some serious due diligence behind it!"
Is there any other board with as much Due Diligence is this one? We have scientists; old people with wisdom and knowledge; people with knowledge without any wisdom, uuhh?; penny flippers; and real investors who know what they OWN!!
AMBS
Good morning Jeffshir,
Us Teachers and lowlife, and Walmart shoppers get paid tomorrow; I guess we'll be buying again @ Walmart's low, low, low price!!! GREEN LIGHT PRICES$$$
PEACE
Yes, and still accumulating shares @
Walmart's low..low prices every pay period... Every two weeks!!!! So bank your mouth and comments on that$$$$
People are noted on this board for saying "connecting the dots were for "DUMMIES"...
than, sign me up!!! I AM ONE OF THE DUMMIES THAT'S BELIEVING IN ALL THESE DOTS'
"YOU CAN LEARN ALOT FROM A DUMMY" !!! LOL
AMBS
News for 'AMBS' - (Amarantus Posts New White Paper to Its Web Site)
May 06, 2013 (Close-Up Media via COMTEX) -- Amarantus BioScience Holdings,
Inc., a biotechnology company discovering and developing treatments and
diagnostics for diseases associated with neurodegeneration and apoptosis, has
posted to its Web site a White Paper titled "A Review of MANF Literature:
Implications for the Development Program of Amarantus Bioscience Holdings."
"This extensive report on our lead therapeutic MANF is valuable to a number of
audiences, including life science research professionals, potential development
partners, and investors as they conduct due diligence to better understand the
breadth of the technology," said Amarantus Chief Executive Officer Gerald
Commissiong. "It is the most comprehensive discussion of the properties and
potential of MANF, and we believe it will significantly enhance understanding of
our MANF therapeutic program."
Prepared by the consulting firm NeuroAssets, the 41-page report covers MANF's
protein structure and cellular activities; studies related to Parkinson's
disease, stroke, myocardial infarction and traumatic brain injury; and the
potential for further development of MANF, the Company noted in a release.
Amarantus said that MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
is believed to have broad potential because it is a naturally-occurring protein
produced by the body for the purpose of reducing and preventing apoptosis (cell
death) in response to injury or disease, via the unfolded protein response. By
manufacturing MANF and administering it to the body, Amarantus is seeking to use
a regenerative medicine approach to assist the body with higher quantities of
MANF when needed. Amarantus is the front-runner and primary holder of
intellectual property (IP) around MANF, and is initially focusing on the
development of MANF-based protein therapeutics. MANF's current lead indication
is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI).
Future indications may include myocardial infarction and certain rare and
ultra-rare orphan diseases for which MANF is currently being evaluated.
NeuroAssets identifies and manages the development of neuroscience assets that
focus on diseases of the nervous and muscle systems. NeuroAssets was founded by
David A. Lowe PhD, based on his international experience of Nervous System R&D
in Pharma, Biotech and Venture Capital Companies. The company is based in Vevey
on Lake Geneva, Switzerland, and works with business partners in the U.S.,
Europe, Middle East and Asia.
White Paper:
http://ir.stockpr.com/amarantus/scientific-publications
They're just like the FED.... PRINT AND SELL.. PRINT AND SELL!!! and repeat.
ugns
Is 9 billion enough? They have more where this came from!!
ungs
Good luck to you too as well UNEASY!....I am praying to god that whilst we are saying our goodbye's, that you wouldn't be under the disguise of an investor... and actually saying "goodbye suckers...I'M AN ANDERSON?"
UNGS
have a good one uneasy!
I'm in!!! Take a small position. Tia Mr Dale!
Lol, Mr Dale
What about it? What should we all know that you know?? Chetra744??
UnEasy.... I think he is hinting to go and INVEST....in AMBS...it is a winner... won't happen over night.. though the probability of you making a nice return on your investment is more than likely; than UNGS getting to .01 cents!
This will have to be your decision; though this has been a complete "wait and see"...wait and see Chetra get outa jail on May 29,2013.!
Upon Chetra's release still a "wait and see" !
UNGS
Scottrade...
Bid/Size
0.047 / 61,000,000
Ask/Size
0.048 / 41,211,900
And I believe!!!!
I called Ameritrade and the broker stated the symbol " AMBS "is available to be bought and trade!!!
:)
Scottrade is Available for trading AMBS